From: Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma
Parameter | GAB2 n (%) | P | CRKL n (%) | P | FRS2 n (%) | P | GAB2/CRKL/FRS2 n (%) | P | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | Negative | Positive | Negativea | Positiveb | |||||
Sex | 1.000 | 1.000 | 1.000 | 0.762 | ||||||||
Female | 22(61.1%) | 14(38.9%) | 17(47.2%) | 19(52.8%) | 23(63.9%) | 13(36.1%) | 29(80.6%) | 7(19.4%) | ||||
Male | 23(59.0%) | 16(41.0%) | 18(45.0%) | 22(55.0%) | 27(65.9%) | 14(34.1%) | 35(85.4%) | 6(14.6%) | ||||
Age at diagnosis | 1.000 | 0.645 | 0.811 | 1.000 | ||||||||
≤ 60 | 21(60.0%) | 14(40.0%) | 18(50.0%) | 18(50.0%) | 25(67.6%) | 12(32.4%) | 31(83.6%) | 6(16.2%) | ||||
> 60 | 24(60.0%) | 16(40.0%) | 17(42.5%) | 23(57.5%) | 25(62.5%) | 15(37.5%) | 33(82.5%) | 7(17.5%) | ||||
Size (diameter), | 0.255 | 0.260 | 0.557 | 0.452 | ||||||||
≤ 2 cm | 7(46.7%) | 8(53.3%) | 5(31.3%) | 11(68.7%) | 9(56.3%) | 7(43.8%) | 12(75.0%) | 4(25.0%) | ||||
> 2 cm | 38(63.3%) | 22(36.7%) | 30(50.0%) | 30(50.0%) | 41(67.2%) | 20(32.8%) | 52(85.2%) | 9(14.8%) | ||||
Tumor sites | 0.246 | 0.645 | 0.161 | 0.367 | ||||||||
Head | 26(66.7%) | 13(33.3%) | 17(42.5%) | 23(57.5%) | 29(72.5%) | 11(27.5%) | 35(87.5%) | 5(12.5%) | ||||
Body/Tail | 19(52.8%) | 17(47.2%) | 18(50.0%) | 18(50.0%) | 21(56.8%) | 16(43.2%) | 29(78.4%) | 8(21.6%) | ||||
Resection margins | 1.000 | 1.000 | 1.000 | 1.000 | ||||||||
Negative | 37(59.7%) | 25(40.3%) | 29(46.0%) | 34(54.0%) | 41(64.1%) | 23(35.9%) | 53(82.8%) | 11(17.2%) | ||||
Positive | 8(61.5%) | 5(38.5%) | 6(46.2%) | 7(53.8%) | 9(69.2%) | 4(30.8%) | 11(84.6%) | 2(15.4%) | ||||
Differentiation | 1.000 | 0.187 | 0.581 | 0.288 | ||||||||
Well/moderate | 34(60.7%) | 22(39.3%) | 29(50.9%) | 28(49.1%) | 39(67.2%) | 19(32.8%) | 50(86.2%) | 8(13.8%) | ||||
Poor | 11(57.9%) | 8(42.1%) | 6(31.6%) | 13(68.4%) | 11(57.9%) | 8(42.1%) | 14(73.7%) | 5(26.3%) | ||||
Nodal metastasis | 0.640 | 0.642 | 0.337 | 0.122 | ||||||||
No | 17(56.7%) | 13(43.3%) | 13(41.9%) | 18(58.1%) | 18(58.1%) | 13(41.9%) | 23(74.2%) | 8(25.8%) | ||||
Yes | 28(62.2%) | 17(37.8%) | 22(48.9%) | 23(51.5%) | 32(69.6%) | 14(30.4%) | 41(89.1%) | 5(10.9%) | ||||
TNM stage | 1.000 | 1.000 | 1.000 | 1.000 | ||||||||
I/II | 38(60.3%) | 25(39.7%) | 30(46.2%) | 35(53.8%) | 42(64.6%) | 23(35.4%) | 54(83.1%) | 11(16.9%) | ||||
III/IV | 7(58.3%) | 5(41.7%) | 5(45.5%) | 6(54.5%) | 8(66.7%) | 4(33.3%) | 10(83.3%) | 2(16.7%) |